Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale related to an exercise of stock options of 18,606 shares of Common stock on 05/07/2026 for cash. The filing also lists recent 10b5-1 sales by Christopher Sullivan totaling multiple transactions in April–May 2026, including a 47,000-share sale on 05/06/2026.
Avalo Therapeutics Chief Legal Officer Paul Varki reported a mix of option exercises and share sales in Avalo Therapeutics, Inc. common stock. On May 6, 2026, he exercised stock options to acquire a total of 75,063 shares of common stock at exercise prices of $8.04 and $13.43 per share.
On the same date, he sold 75,063 shares of common stock in open-market transactions at prices ranging from $18.50 to $22.88 per share. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance as part of a trading program.
Avalo Therapeutics, Inc.'s Chief Financial Officer, Christopher Ryan Sullivan, reported a combination of stock sales and option exercises. On May 6, 2026, he executed open-market sales totaling 47,000 shares of Avalo Therapeutics common stock in multiple tranches under a Rule 10b5-1 trading plan adopted on November 12, 2025, at prices ranging from $17.95 to $22.88 per share.
On the same date, he exercised stock options to acquire 47,000 common shares at an exercise price of $8.04 per share. Following these transactions, he directly holds 47,423 shares of common stock and 116,000 stock options that are scheduled to vest over time and expire on January 28, 2035.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported option exercises and related share sales in Avalo Therapeutics, Inc. common stock. On May 5–6, 2026, she exercised stock options covering 108,234 shares at strike prices of $8.04 and $12.65 per share and sold 108,234 shares in open-market transactions.
The sales occurred at prices ranging from $16.00 to about $22.88, executed in multiple trades. According to a footnote, all transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Avalo Therapeutics, Inc. director Mitchell Chan executed an open-market sale of 3,167 shares of Common Stock at $22.88 per share. The transaction occurred on May 6, 2026 and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, Chan directly holds 3,166 shares of Avalo Therapeutics common stock.
Avalo Therapeutics, Inc. entered into an underwriting agreement to sell 19,730,000 shares of common stock at $17.75 per share and pre-funded warrants to purchase up to 1,400,000 shares at $17.749 per warrant in a public offering. Underwriters also exercised in full a 3,169,500-share option at the public offering price.
The company expects approximately $405.0 million in net proceeds, which, together with its cash, cash equivalents and short-term investments, was estimated at $82.0 million as of March 31, 2026. As of May 4, 2026, 29,326,347 common shares were outstanding.
Avalo plans to use the funds to advance the clinical development of abdakibart, including through its Phase 3 topline data release, and for working capital and general corporate purposes. Based on current plans, it believes this capital will fund operations into 2029.
Avalo Therapeutics is offering 19,730,000 shares of common stock and pre-funded warrants to purchase up to 1,400,000 additional shares. The offering price is $17.75 per share and each pre-funded warrant has an exercise price of $0.001 per share. The company estimates net proceeds of approximately $352.1 million, which it intends to use to advance the clinical development of abdakibart (AVTX-009) into a Phase 3 registrational program, for working capital and general corporate purposes. Avalo reported $82.0 million of cash, cash equivalents and short-term investments as of March 31, 2026. The pre-funded warrants are non‑expiring, subject to ownership limits (4.99% default; holder may elect 9.99%), and are not expected to be listed.
AVTX-related sale notice: A broker-dealer filing lists 54,508 shares of Common Stock to be sold on 05/06/2026 pursuant to an exercise of stock options for cash. The filing also lists recent 10b5-1 programmed sales by Mittie Doyle totaling multiple transactions during March–May 2026.
AVTX reported proposed transactions relating to company common stock. The filing lists an exercise of stock options for 47,000 shares on 05/06/2026 (cash to issuer) and records recent 10b5-1 sales of 8,457, 8,458, 7,980, and 7,979 shares on 04/30/2026, 04/29/2026, 04/02/2026, and 04/01/2026 respectively, with dollar proceeds shown for each sale.